[1] Beuers U,Gershwin ME,Gish RG,et al.Changing nomenclature for PBC:From‘cirrhosis’ to ‘cholangitis’. Gut,2015,64(11):1671-1672.
[2] Carey EJ,Ali AH,Lindor KD.Primary biliary cirrhosis. Lancet,2015,386(10003):1565-1575.
[3] Liu H,Liu Y,Wang L,et al.Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol,2010,4(10):100-103.
[4] Victoria G,Anita L,Vgren S,et al.The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PLoS One,2014,9(1):e83-828.
[6] Hirschfield GM.Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol,2011,25(6):701-712.
[7] 张作记. 行为医学量表手册. 北京: 中华医学电子音像出版社,2001:131-132.
[8] Silveira MG,Burnt EM,Heathcote J,et al.American associationfor the study of liver diseases endpoints conference:design and endpoints for clinical trials in primary biliary cirrhosis. J Hepatol,2010,25(1):349-359.
[9] Griffiths L,Dyson JK,Jones DE.The new epidemiology of primary biliary cirrhosis. Semin Liver Dis,2014,34(3):318-328.
[10] Poupon R.Ursodeoxycholic acid and bile-acid mimetics astherapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol,2012,36(Suppl 1):S3-S12.
[11] Rautiainen H,Karkkainen P,Karvonen AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three -year randomized trial. Hepatology,2005,41(4):747-752.
[12] Dempster DW,Lambing CL,Kostenuik PJ,et al.Role of RANK ligand and denosumab,a targeted RANK ligand inhibitor,in bone health and osteoporosis:a review of preclinical and clinical data. Clin Ther,2012,34:521-536.
[13] Mason AL,Lindor KD,Bacon BR,et al.Clinical trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther,2008,28(7):886-894.
[14] Leung J,Bonis PA,Kaplan MM.Colchicine or methotrexate,with ursodiol,are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol,2011,9(9):776-780.
[15] Lyu JL,Jin SY,Yuan HL,et al.Rational daily administration times of Yinchenhao decoction in rats with jaundice based on PD/PK. Chin Herbal Med,2012,4(2):150.
[17] Appourchaux K,Dokmak S,Resche-Rigon M,et al.MicroRNA-based diagnostic tools foradvanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep,2016,6:34935.
[18] 孔祥璐,郭晓霞. 中药联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化疗效系统评价. 实用肝脏病杂志,2015,18(4):379-382.
[19] Angulo P,Jorgensen RA,Keach JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology,2000,31(2):318-323.
[20] Hu Q,Noor M,Wong YF,et al.In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant,2009,24(10):3033-3041. |